FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Novel Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) under Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AXA1665

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 26, 2020

            Details:

            IND submission for overt hepatic encephalopathy and initiation of potential registrational Phase 2b/3 clinical trial planned for second half of 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

            Deal Size: $12.2 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 21, 2020

            Details:

            The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AXA1125

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2020

            Details:

            Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks.